← ANALYST RATINGS · TIPRANKS
ArriVent BioPharma, Inc. (AVBP): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $24.56, the highest $50.00, the lowest $15.00. The average is +47.4% from the last price of $16.66.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $16.00 → $15.50−3.1% | Sell | −7.0% | Reiterated | 13.10.26on TipRanks 15:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $16.50 → $16.00−3.0% | Hold | −4.0% | Reiterated | 13.10.26on TipRanks 15:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $16.00 → $15.50−3.1% | Sell | −7.0% | Reiterated | 13.10.26on TipRanks 15:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $17.00 → $15.50−8.8% | Sell | −7.0% | Downgrade | 13.10.26on TipRanks 15:05 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $27.00 | Buy | +62.1% | Reiterated | 13.10.26on TipRanks 06:26 | −2.2%next day +1.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $15.50 → $16.50+6.5% | Hold | −1.0% | Reiterated | 08.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.50 → $16.00+10.3% | Hold | −4.0% | Reiterated | 08.10.26on TipRanks 17:05 | — | |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $45.00 → $18.00−60.0% | Buy | +8.0% | Assigned | 07.10.26on TipRanks 06:50 | +12.2%next day −0.6% · 5 days −3.1% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $42.00 → $29.00−31.0% | Buy | +74.1% | Reiterated | 06.10.26on TipRanks Oct 7 05:25 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $40.00 → $20.00−50.0% | Buy | +20.0% | Reiterated | 06.10.26on TipRanks Oct 7 05:25 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $47.00 → $22.00−53.2% | Buy | +32.1% | Reiterated | 06.10.26on TipRanks Oct 7 04:06 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Supawat Thongthip★★★★★★★★★★#6413 · hits 70% · avg +6.4% | Truist Financial | $45.00 → $18.00−60.0% | Buy | +8.0% | Reiterated | 06.10.26on TipRanks Oct 7 02:06 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Kelly Shi★★★★★★★★★★#3014 · hits 44% · avg +5.9% | Jefferies | $45.00 → $18.00−60.0% | Buy | +8.0% | Reiterated | 06.10.26on TipRanks Oct 7 02:06 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $45.00 → $22.00−51.1% | Buy | +32.1% | Reiterated | 06.10.26on TipRanks 15:50 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $43.00 → $15.00−65.1% | Buy | −10.0% | Reiterated | 06.10.26on TipRanks 11:30 | −47.5%next day +12.2% · 5 days +6.8% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $45.00 | Buy | +170.1% | Reiterated | 13.08.26on TipRanks 07:50 | −5.3%next day −1.4% · 5 days −0.8% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $50.00 | Buy | +200.1% | Reiterated | 13.08.26on TipRanks 07:50 | −5.3%next day −1.4% · 5 days −0.8% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $45.00 | Buy | +170.1% | Reiterated | 29.05.26on TipRanks Jun 1 09:10 | +12.0%next day +1.1% · 5 days +2.8% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | — | Buy | — | Initiated | 22.12.25on TipRanks 16:25 | −0.8%next day −0.5% · 5 days −9.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ArriVent BioPharma, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $44.57 at a price of $30.28 (+47.2%); now: $25.82 at $16.66 (+55.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 9 | 6 | 4 | 5 | 8 |
| Buy | 10 | 10 | 12 | 11 | 9 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.06 (from $-1.16 to $-1.00). Last quarter: $-1.05.
Best top-analyst consensus in the sector · Healthcare
About ArriVent BioPharma, Inc.
- CEO: Zhengbin Yao
- Employees: 77
- 18 Campus Boulevard Suite 100, Newtown Square, PA, 19073, US
- arrivent.com
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 44 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗